fizkes / Shutterstock.com
29 June 2023Big PharmaLiz Hockley
US appeals court upholds decision on wrinkle treatment
Board did not violate procedure regarding ‘preliminary guidance’ say Federal Circuit judges | Medytox’s substitute claims found to be ‘unpatentable’.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
20 July 2021 The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Editor's picks
Editor's picks
Big Pharma
20 July 2021 The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.
Big Pharma
20 July 2021 The Patent Trial and Appeal Board has ruled that a Medytox patent for its wrinkle treatment should not have been granted.
Americas
30 January 2020 The US Court of Appeals for the Federal Circuit has revived patent infringement litigation brought against Teva by dermatological company Galderma, a former subsidiary of Nestlé Skin Health.